Alexion Prescription drugs Inc. ALXN mentioned late Wednesday it stopped enrolling sufferers in a medical examine testing a therapy for extreme COVID-19 sufferers based mostly on the advice of an information monitoring board. The unbiased knowledge monitoring committee for the Section Three examine of the drug Ultomiris mentioned additional enrollment of sufferers needs to be paused pending extra knowledge evaluation because the therapy was not seeking to be efficient in treating COVID-19 sufferers on ventilators when put next with customary care, the corporate mentioned. Alexion mentioned it is going to proceed treating present sufferers and that no new security considerations have been discovered. Alexion shares declined 0.3% after hours, following a 0.5% rise within the common session to shut at $156.44.Market Pulse Tales are Speedy-fire, brief information bursts on shares and markets as they transfer. Go to MarketWatch.com for extra data on this information.
Learn Full Story
2021-01-13